Compare MSI & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSI | INM |
|---|---|---|
| Founded | 1928 | 1981 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6B | 3.6M |
| IPO Year | N/A | N/A |
| Metric | MSI | INM |
|---|---|---|
| Price | $395.08 | $1.15 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $487.33 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 97.9K |
| Earning Date | 02-12-2026 | 02-11-2026 |
| Dividend Yield | ★ 1.24% | N/A |
| EPS Growth | ★ 36.31 | N/A |
| EPS | ★ 12.46 | N/A |
| Revenue | ★ $11,313,000,000.00 | $4,798,116.00 |
| Revenue This Year | $8.75 | N/A |
| Revenue Next Year | $8.24 | N/A |
| P/E Ratio | $31.39 | ★ N/A |
| Revenue Growth | ★ 6.18 | N/A |
| 52 Week Low | $359.36 | $1.03 |
| 52 Week High | $492.22 | $8.27 |
| Indicator | MSI | INM |
|---|---|---|
| Relative Strength Index (RSI) | 59.29 | 46.44 |
| Support Level | $390.65 | $1.03 |
| Resistance Level | $403.22 | $1.40 |
| Average True Range (ATR) | 7.29 | 0.09 |
| MACD | 1.81 | 0.01 |
| Stochastic Oscillator | 66.15 | 35.14 |
Motorola Solutions is a leading provider of communications and analytics, primarily serving public safety departments as well as schools, hospitals, and businesses. The bulk of the firm's revenue comes from sales of land mobile radios and radio network infrastructure, but the firm also sells surveillance equipment, dispatch software, and other networking capabilities. Most of Motorola's revenue comes from government agencies, while roughly 25% comes from schools and private businesses. Motorola has customers in over 100 countries and in every state in the United States.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.